Caption Management, LLC Sage Therapeutics, Inc. Transaction History

Caption Management, LLC

$6.26 Billion
Q1 2024

A detailed history of Caption Management, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Caption Management, LLC holds 30,000 shares of SAGE stock, worth $318,600. This represents 0.01% of its overall portfolio holdings.

Number of Shares

30,000

Previous 30,000 -0.0%

Holding current value

$318,600

Previous $650,000 13.54%

% of portfolio

0.01%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$18.62 - $26.95 $33,888 - $49,049	1,820 Added 59.28%	4,890 $91,000
Q4 2023 Feb 14, 2024	SELL	$17.1 - $22.26 $321,480 - $418,488	-18,800 Reduced 85.96%	3,070 $66,000
Q3 2023 Nov 14, 2023	BUY	$16.75 - $48.98 $366,322 - $1.07 Million	21,870 New	21,870 $450,000
Q2 2022 Aug 15, 2022	SELL	$27.52 - $37.99 $1.65 Million - $2.28 Million	-59,935 Reduced 93.22%	4,362 $141,000
Q1 2022 May 13, 2022	SELL	$30.71 - $45.71 $71,370 - $106,230	-2,324 Reduced 3.49%	64,297 $2.13 Million

Q4 2021 Feb 11, 2022	SELL	$37.06 - $47.11 $2.7 Million - $3.44 Million	-72,979 Reduced 52.28%	66,621 $2.84 Million
Q2 2021 Aug 16, 2021	BUY	$54.88 - $79.29 $7.07 Million - $10.2 Million	128,770 Added 1189.01%	139,600 $7.93 Million
Q1 2021 May 17, 2021	SELL	$70.65 - $96.76 $3.85 Million - $5.27 Million	-54,470 Reduced 83.42%	10,830 $810,000
Q4 2019 Feb 13, 2020	BUY	$60.18 - $154.77 $1.49 Million - $3.82 Million	24,700 Added 60.84%	65,300 $4.72 Million
Q1 2019 May 14, 2019	BUY	$89.33 - $163.65 $1.59 Million - $2.9 Million	17,750 Added 77.68%	40,600 $6.46 Million
Q4 2018 Jan 30, 2019	BUY	$81.94 - $139.71 $1.87 Million - $3.19 Million	22,850 New	22,850 $2.19 Million

Others Institutions Holding SAGE

# of Institutions

222

Shares Held

52.7M

Call Options Held

207K

Put Options Held

191K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $631M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Caption Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Caption Management, LLC with notifications on news.

Account

Caption Management, LLC Sage Therapeutics, Inc. Transaction History